Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function - Wikidata - awgldk - TriplyDB

Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function

Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function

http://www.wikidata.org/entity/Q36498379

about

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation Evolutionary divergence and functions of the human interleukin (IL) gene family Interleukin-32δ interacts with IL-32β and inhibits IL-32β-mediated IL-10 production Bone Marrow Immunity and Myelodysplasia Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Infections in myelodysplastic syndromes Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia Interleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.IL-32 promotes angiogenesis.Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis.Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.Dietary blue pigments derived from genipin, attenuate inflammation by inhibiting LPS-induced iNOS and COX-2 expression via the NF-κB inactivation.Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis.Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells.IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals.Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model.Biology of BM failure syndromes: role of microenvironment and niches.The anti-inflammatory activities of ethanol extract from Dan-Lou prescription in vivo and in vitro.NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy.Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma DNA methylation and gene expression profiling of ewing sarcoma primary tumors reveal genes that are potential targets of epigenetic inactivation.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD.IL-32-dependent effects of IL-1beta on endothelial cell functions No telomere shortening in marrow stroma from patients with MDS.Molecular characterization of IL-32 in human endothelial cells Modeling human hematopoietic stem cell biology in the mouse.Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.Interleukin-32α induces migration of human melanoma cells through downregulation of E-cadherin.Leukemia stem cells and microenvironment: biology and therapeutic targeting.Immune alterations in untreated and treated myelodysplastic syndrome.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Molecular biology of myelodysplastic syndromes.Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis.Role of interleukin-32 in chronic rhinosinusitis Novel insights into the biology of interleukin-32.An evolutionary perspective on chronic myelomonocytic leukemia.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

P2860

Q21092154-89C96A8B-6CF0-44D2-A2E9-E3B9E68A9F68 Q21245454-D4132D98-5003-4380-9967-D40893C8E65D Q24317887-AE0F43C1-82C0-4F63-A963-F0C6B5B1D899 Q26739239-5414711D-81A1-4A67-A90B-B3E22448C816 Q26746104-550A09D6-44EB-492B-8E89-C190D8C21030 Q26859275-1478E995-32AB-4407-9CBB-0B11E0E5046D Q28307278-F89DAB5C-37CA-4E8C-BB15-C9AA64346399 Q30411120-4992C058-B867-4069-858F-FA56E3FE49C1 Q33555523-E2E909DC-387C-46C7-B3A6-9CBD02C6F3CF Q33722724-ECD9DE72-7031-4965-BC6E-DEC2F7585ED8 Q33733541-EAFDA730-2884-4C49-834A-6986687FB257 Q34193321-9361F613-3285-4EAD-88C3-7FED41C82CA2 Q34222153-690B5443-B576-4398-AD5F-9F43F9FAAF59 Q34720467-88033E1E-AD38-4E5A-A6E2-2EF8EA6B79AB Q34752043-A8987217-1FCC-4593-B307-8FA19628650C Q35134651-12C52CD5-30FF-43DE-91EB-65F4EBC5936B Q35525740-92581A64-A865-437D-9E10-DDE32A2D5701 Q35568527-6075B77C-B3A6-4C30-A415-AE2A7928609E Q35768547-19EEEB87-F13A-4CE9-B71B-C7F5583E7FD4 Q35948586-44F28CD6-23CE-4B65-8D4C-E6CDA681818A Q35995303-0CA35297-83CD-487E-95F2-90978798FBD1 Q36248516-210B92AF-A2F7-4BA2-9641-5154820264F1 Q36339459-50C607EE-5419-4DE1-94BA-3C8D12ABD001 Q37066254-B0BBB180-F1AC-496D-894F-AF00BC07E6D8 Q37129422-090E9B90-4DCB-4B73-8145-AD53B70799D0 Q37219621-FE21AF79-45A5-4738-B23A-EE5449734B8A Q37248214-6A6C24B5-B644-4D19-8CAD-5075E52B36AA Q37303855-F190EED5-7B23-41B7-AB47-D8558C5D9BC5 Q37562510-0479A4B8-C7EE-4596-A9E7-F2296A72EEC3 Q37584726-36AB5F1D-2534-4FCE-8EEE-272FA21C2581 Q37662318-F0D02A04-2D04-4398-9314-9369CFDF7158 Q37827279-E9EF1D99-6D2E-4515-94AC-644AEF27EC16 Q37854701-83584B54-51FD-48D9-BAF9-B7EE6C502521 Q37864686-578BA34D-82D8-47B1-A736-787E2C5C67E9 Q37937809-2AA4654F-8682-4314-A60D-C7468340D694 Q37973279-BCF936CF-6243-4EE3-9B29-FA7B526B92D1 Q38067583-B1B0B75C-E352-4A21-A656-41489744B785 Q38086768-8BBF467B-C6D5-4A42-AEC4-4110B8B170BE Q38096235-978A6D5D-B90C-451E-9386-BF4E8F50D6AE Q38241774-55A299FF-7059-42F8-A5AD-6BE534686E3B

P2860

Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function

http://www.wikidata.org/entity/Q36498379

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@ast

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@en

type

label

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@ast

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@en

prefLabel

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@ast

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@en

P1433

Q36498379-C973707E-AC25-4CC9-8BB0-6A1A67102BBC

P1476

Q36498379-5BD3E8CA-426B-4C8D-835F-779AC728B70A

P2093

Q36498379-3D19EEB0-8D27-4136-B0CA-B08FEB040633

Q36498379-43A71B72-F28A-4011-988E-C6E556EAD424

Q36498379-87F600ED-B14F-4F04-9AEB-82EB00C2E35B

Q36498379-BE5E5D95-B88B-4A5D-8632-446D73C51A70

P2860

Q36498379-03A8CB54-BDE6-4C07-8693-0E1E4DE06E7C

Q36498379-06508A1F-8BD3-47CC-9AB1-25BD3DEEBA81

Q36498379-1A2EFD9F-A4D9-463E-804B-DFC3472DEE9B

Q36498379-205D1A29-CC3E-45CD-A7B3-A76590599D0C

Q36498379-261566DC-AC8D-4AA4-B78A-7C80DDA06434

Q36498379-30537048-FAED-42F2-B3C9-0698ECA44F00

Q36498379-32E45E61-B548-4601-8755-D2F65C6B9FDD

Q36498379-46FC96D4-933E-48EE-BA5F-EE419ED7A788

Q36498379-49115699-6E34-4E30-A5FE-20A3213C680B

Q36498379-51BCCE76-8340-4A00-9D6C-CD8D69838F01

P304

Q36498379-5988F2BA-06DC-493B-A23E-046A15333600

P31

Q36498379-AF615286-D857-40F1-916B-488C4368CF71

P356

Q36498379-1A4C5FEF-92CF-48FD-AAFE-A42CA01B98F8

P407

Q36498379-0DBBF738-A3E3-4188-9F13-EAA56A9FDB40

P433

Q36498379-2FFFA954-66AD-4A9C-ADA6-D108DF1819BC

P478

Q36498379-03F771C0-2ACC-49B5-A256-DE7FD7B2CD47

P50

Q36498379-818B061D-D697-4448-A2E3-E1E2EA7A0D40

Q36498379-AA05742F-5A3D-43F8-9143-9905410F5F43

P577

Q36498379-E6232DA6-A9E7-4F7C-B57C-5D327E3EE67A

P5875

Q36498379-64038776-5C02-46B3-9FDF-E78579136D40

P698

Q36498379-4038126B-EECD-490B-92DE-2348D168F86E

P921

Q36498379-43F80C04-E60E-4BB3-8F0D-ED42D9257E2F

Q36498379-B1BBBE35-AD75-4AD5-8C85-B53A806F495E

P932

Q36498379-8EC2DCDC-08A4-4FC0-A8F2-C11184AEEECD

P356

PNAS.0712391105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Dysregulation of IL-32 in myel ...... ptosis and impairs NK function

@en

P2093

A Mario Marcondes

http://www.w3.org/2001/XMLSchema#string

Andrew J Mhyre

http://www.w3.org/2001/XMLSchema#string

Derek L Stirewalt

http://www.w3.org/2001/XMLSchema#string

Soo-Hyun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism

Identification of a novel gene expressed in activated natural killer cells and T cells

The World Health Organization (WHO) classification of the myeloid neoplasms

Proposals for the classification of the myelodysplastic syndromes

Interleukin-32: a cytokine and inducer of TNFalpha

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

IL-32, a proinflammatory cytokine in rheumatoid arthritis.

NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)

Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.

IL-32, a novel cytokine with a possible role in disease

P304

2865-2870

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0712391105

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Hans Joachim Deeg

Charles A. Dinarello

P577

2008-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5565098

http://www.w3.org/2001/XMLSchema#string

P698

18287021

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

2268551

http://www.w3.org/2001/XMLSchema#string